Home > Information > BioSpotlight

BioSpotlight

2025-07-30

Understanding Hepatitis C Virus: Structure, Pathogenesis, Vaccine Research & abinScience Tools

Discover the biology, structure, and pathogenesis of Hepatitis C Virus (HCV), including its virion structure and immune evasion strategies. Explore the latest advances in HCV vaccine development and effective tools from abinScience, such as recombinant proteins and antibodies, to support antiviral research. Updated July 30, 2025, this resource offers insights into DAA therapy and vertical transmission challenges.
2025-07-23

Chikungunya Virus in 2025: A Global Health Threat and the Role of Innovative Research

Discover the Chikungunya virus (CHIKV) structure, key proteins, and pathogenesis, with insights from the 2025 Foshan outbreak and global epidemiology. Learn about WHO’s warnings on CHIKV epidemic risks and explore abinScience’s advanced research tools, including recombinant proteins and antibodies, designed to support vaccine and antiviral development for this mosquito-borne disease.
2025-07-07

Combating Mosquito-Borne Diseases: Research Tools and Insights

Uncover the science behind mosquito-borne diseases like Chikungunya’s crippling joint pain, Dengue’s complex serotypes, West Nile’s neurological risks, Yellow Fever’s historic threat, Zika’s congenital dangers, and Japanese Encephalitis’s brain inflammation. Learn about the challenges of controlling these viruses and explore cutting-edge lab tools for diagnostics, vaccine development, and research. abinScience offers specialized antibodies and recombinant proteins to target viral proteins, empowering scientists to fight these global health threats effectively.
2025-05-22

COVID-19 Resurgence in 2025: Omicron NB.1.8.1 Drives Surge with Enhanced Immune Escape

Since April 2025, China has faced a resurgence of COVID-19, with positivity rates in outpatient and inpatient settings rising sharply from 7.5% to 16.2% and 3.3% to 6.3%, respectively. Southern provinces report higher infection rates than the north, with the Omicron NB.1.8.1 variant driving the surge due to its enhanced immune escape capabilities. Symptoms remain mild, including sore throat, low-grade fever, and cough. The pandemic is expected to peak in late May and subside by late June. abinScience offers high-quality SARS-CoV-2-related proteins and antibodies to support cutting-edge virology research.
2025-04-25

InVivoMAb™ Plus: Precision In Vivo Antibodies for Animal Models by abinScience

The abinScience InVivoMAb™ Plus series offers over 400 high-quality in vivo antibodies, validated for purity, specificity, and functionality, ideal for research in cancer, autoimmune diseases, and infectious diseases. This page details the activity validation experiments and ELISA tests of anti-PD-1 and anti-PD-L1 antibodies in mouse models (B16-F10 and CT26), demonstrating significant tumor suppression and antigen-binding capabilities. The product list includes a range of antibodies and isotype controls designed for immune regulation and tumor immunotherapy, supported by batch stability and traceability.
2025-05-07

Science Discovery: The Role of Erythropoietin (EPO) in Tumor Immune Evasion

Recent research has uncovered a critical role for erythropoietin (EPO) in tumor immune evasion. Tumor cells secrete EPO, which, through the EPOR signaling pathway, suppresses the immune function of macrophages, aiding tumors in escaping immune surveillance. Blocking the EPO/EPOR signaling enhances the efficacy of PD-1 immunotherapy, offering a novel strategy for cancer treatment.
2025-08-13

Tuberculosis Research and Scientific Applications in 2025: Advances in Diagnosis, Treatment, and Vaccines

This schematic illustration highlights four key research areas in tuberculosis (TB) studies: ESAT-6/CFP-10 as core antigens for immunodiagnostic platforms (IGRA, ELISPOT), HspX as a biomarker for latent infection and stress response, KatG and InhA as primary targets for drug resistance mechanism analysis, and Ag85 series antigens for vaccine target validation. Designed for scientific publications, this figure supports research in TB diagnostics, immune mechanisms, and drug resistance studies.
2025-08-20

Targeting Microglial Cx43 Hemichannels: A Novel Approach to Alleviate Alzheimer’s Disease Pathology

This study identifies microglial Connexin43 (Cx43) hemichannels as a key target in Alzheimer’s disease (AD). Elevated Cx43 expression in AD patients correlates with disease progression. Knocking out microglial Cx43 in APP/PS1 mice increased compact plaques, reduced neuronal damage and oxidative stress, and improved cognition without changing plaque numbers. A selective Cx43 inhibitor, TAT-Cx43@LNPs, delivered via lipid nanoparticles, suppressed hemichannel activity, shifted microglia to a neuroprotective state, and alleviated AD pathology. Early intervention delayed disease progression, highlighting Cx43’s clinical potential.
2025-08-15

AKT1-Mediated SOX2 Stabilization Drives Ovarian Cancer Stemness and Chemoresistance

A study by East China Normal University, published in Scientific Reports, uncovers the role of AKT1 in stabilizing SOX2 protein through T116 phosphorylation, promoting stemness and chemoresistance in ovarian cancer. The research demonstrates that the AKT1 inhibitor MK2206 synergizes with platinum-based drugs, reducing SOX2 levels and enhancing therapeutic efficacy. This suggests that targeting the AKT1–SOX2 axis could offer a promising strategy to overcome chemoresistance in SOX2-positive ovarian cancer, pending further clinical validation.
2025-08-14

Unveiling the WHO-Prioritized Nipah Virus: Deadly Bat-Borne Pathogen Uncovered

This article provides a comprehensive overview of the Nipah virus (NiV), a highly lethal bat-borne pathogen causing severe respiratory and neurological diseases. It explores NiV’s global distribution, viral structure, protein functions, pathogenesis mechanisms, and epidemiological history, highlighting outbreaks in India and Bangladesh. Recent research progress, including vaccine and antibody developments, is discussed, alongside key research targets like the G protein and Ephrin-B2/B3 receptors. abinScience offers specialized proteins and antibodies to support NiV research, empowering scientists in their pursuit of solutions against this priority pathogen.
2025-08-07

Combined BCL11A Enhancer Editing and CD45-ADC Preconditioning for Long-Term HbF Induction in β-Hemoglobinopathies

This study demonstrates a novel gene therapy approach for β-hemoglobinopathies, such as sickle cell disease and β-thalassemia, by simultaneously editing the +55 and +58 enhancers of BCL11A to efficiently induce fetal hemoglobin (HbF) expression. Combined with CD45 antibody-drug conjugate (ADC) preconditioning, this strategy achieves long-term, safe, and effective HbF reactivation in rhesus macaques, offering a chemotherapy-free alternative with high engraftment efficiency and minimal off-target effects, paving the way for curative treatments.
2025-08-05

JAK2 V617F Mutation and Its Role in Coronary Plaque Erosion

This study, published in European Heart Journal, investigates the JAK2 V617F mutation’s association with coronary plaque erosion, revealing a significant link (over 10-fold increased risk). Using digital droplet PCR and single-cell RNA sequencing, it demonstrates that JAK2 V617F enhances neutrophil activation and NETosis, driving plaque erosion. These findings provide a basis for precise cardiovascular risk stratification and support targeted JAK2 therapies.

Get a free quote